Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.”In the company’s words, NCT05071430 on ClinicalTrials.gov
- Tested for
- Panic Disorder
- Main trialPhase 2
- “The purpose of this study is to determine the safety and efficacy of potential new treatment called "HB-1" versus placebo in male and female adult patients aged 18 to 60 years, inclusive, with panic disorder.”In the company’s words, NCT05071430 on ClinicalTrials.gov
- Other names
- Active Drug
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 12 Dec 2022 | Safety and Efficacy of HB-1 for Panic Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026